



Insights Into *SND1* Oncogene Promoter Regulation

Begoña Ochoa, Yolanda Chico and María José Martínez*

Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain

The staphylococcal nuclease and Tudor domain containing 1 gene (*SND1*), also known as *Tudor-SN*, *TSN* or *p100*, encodes an evolutionarily conserved protein with invariant domain composition. *SND1* contains four repeated staphylococcal nuclease domains and a single Tudor domain, which confer it endonuclease activity and extraordinary capacity for interacting with nucleic acids, individual proteins and protein complexes. Originally described as a transcriptional coactivator, *SND1* plays fundamental roles in the regulation of gene expression, including RNA splicing, interference, stability, and editing, as well as in the regulation of protein and lipid homeostasis. Recently, *SND1* has gained attention as a potential disease biomarker due to its positive correlation with cancer progression and metastatic spread. Such functional diversity of *SND1* marks this gene as interesting for further analysis in relation with the multiple levels of regulation of *SND1* protein production. In this review, we summarize the *SND1* genomic region and promoter architecture, the set of transcription factors that can bind the proximal promoter, and the evidence supporting transactivation of *SND1* promoter by a number of signal transduction pathways operating in different cell types and conditions. Unraveling the mechanisms responsible for *SND1* promoter regulation is of utmost interest to decipher the *SND1* contribution in the realm of both normal and abnormal physiology.

Keywords: staphylococcal nuclease and Tudor domain containing 1, Tudor-SN, transcriptional regulation, chromosome 7 band 7q.32.1, miR-593, *SND1*-IT1, oncogene promoter

OPEN ACCESS

Edited by:

Markus A. N. Hartl,
University of Innsbruck, Austria

Reviewed by:

John Strouboulis,
King's College London,
United Kingdom
Francesco Trapasso,
Università degli studi Magna Græcia di
Catanzaro, Italy

*Correspondence:

María José Martínez
mariajose.martinez@ehu.eus

Specialty section:

This article was submitted to
Molecular and Cellular Oncology,
a section of the journal
Frontiers in Oncology

Received: 03 October 2018

Accepted: 27 November 2018

Published: 11 December 2018

Citation:


Ochoa B, Chico Y and Martínez MJ
(2018) Insights Into *SND1* Oncogene
Promoter Regulation.
Front. Oncol. 8:606.
doi: 10.3389/fonc.2018.00606

INTRODUCTION

Staphylococcal nuclease (SN) and Tudor domain containing 1 (*SND1*) gene encodes *SND1*, an evolutionarily conserved multidomain protein also called Tudor-SN, TSN or p100 (1–4). The invariant domain composition of *SND1* comprises a tandem of four SN-like domains at the N-terminus (SN1–4) followed by a C-terminal domain formed by a fusion of a Tudor domain and a truncated SN domain (5) (Figure 1). The potent interaction capacity of SN domains with RNA (6) and of the Tudor domain with modified (methylated) aminoacids (7, 8), together with its intrinsic endonuclease activity (9) for degrading double-stranded RNA (10) enable *SND1* for participating in an unusual multiplicity of functions (summarized in Figure 1). We refer the reader to some recent reviews addressing the biochemistry and function of this protein (11–13).

It has now become clear that the SND family members behave as global regulators of gene expression. *SND1* was first characterized as a transcriptional coactivator, interacting with several

Abbreviations: ATF, activating transcription factor; ER, endoplasmic reticulum; miRNA, microRNA; NF-κB, necrosis factor κB; *SND1*, staphylococcal nuclease and tudor domain containing 1; SRE, sterol response element; SREBP, SRE binding protein; TNFα, tumor necrosis factor α; UPR, unfolded protein response; XBP1, X-box binding protein 1.



transcription factors, including EBNA2 (5, 14), c-Myb (15), STAT6 (16), STAT5 (17), E2F1 (18), and PPAR γ (19). Moreover, the SND1-mediated post-transcriptional regulation is surprisingly diverse. It includes spliceosome assembly and pre-mRNA splicing (20, 21), RNA interference, stability and editing (6, 9, 10), microRNA (miRNA) decay (22), and RNA protection in stress granules (23, 24). In addition, it has been illustrated a role for SND1 in the regulation of protein synthesis, ubiquitination and proteasomal degradation (25, 26).

Clinical and experimental studies show a close association between overexpression of SND1 and progression and aggressiveness of a spectrum of common cancers that include colon, breast, prostate, lung, glioma, melanoma, and liver cancer (27–34). Using different models, researchers have identified a host of mechanisms through which SND1 modulates prosurvival and proliferative genes promoting carcinogenesis. Of particular relevance are the networks involving NF- κ B activation and miR-221 induction (32), miR-184 expression and JAK/STAT3 inhibition (34), TGF β 1/Smad signaling pathway (25), Wnt/ β -catenin activation (27), ERK, and Akt activation (35, 36), as well as the interaction of SND1 with partner proteins like metadherin-1 (30, 37) and monoglyceride lipase (26).

Since full or organ-selective SND1-knockout animal models are not yet available, the systemic role of SND1 remains to be fully delineated. Several works have shown that knocking

down endogenous SND1 inhibits proliferation in diverse cancer cell lines (23, 29, 37–39). As physical interaction of SND1 with E2F1 is critical for the G1/S phase transition (18), the cell cycle arrest in SND1-knockout cells has been attributed to the absence of the SND1-driven endonucleolytic degradation of specific miRNAs that downregulate crucial proteins for the G1/S transition, including E2F1 (18, 40). In addition, other studies have reported that SND1 knockdown fosters apoptosis (41), reduces RISC activity (29, 37), and impairs the aggregation of stress granules (23).

The oncogenic functions assigned to SND1 might be also regarded as a result of its ubiquitous expression in tissues (42) and its ample capacity for interacting with nucleic acids, individual proteins, and protein complexes in the cytoplasmic (43–45) and nuclear compartments (46). Consistent with this, we recently documented that, in human hepatoma HepG2 cells, nuclear SND1 interacted with the genomic DNA to hook SND1 on the promoter of a broad number of target genes modulating cell growth, oncogenic transformation, viral infection and metabolic regulation (47).

Extensive rewiring of lipid metabolism and lipogenic phenotypes are features that distinguish cancer cells from normal cells (48, 49). Besides providing energy and building units for the newly forming cells, lipids generate a network of protumorigenic signals that promote tumor growth (49).

Strong evidence support a role for SND family members in lipid homeostasis. Particularly illustrative are their implication on specific aspects of lipid bodies biogenesis and the secretion of milk lipids by mammary epithelial cells (43, 50), the secretion of lipoprotein particles by liver parenchymal cells (45, 51), and the expression of genes regulating glycerophospholipid homeostasis and phosphatidylcholine content in HepG2 cells during inflammation (47). Interestingly, recent findings have revealed that SND1 overexpression alters cholesterol synthesis and limits triglyceride synthesis via modulation of the regulatory cholesterol pool in endoplasmic reticulum, thus suggesting that SND1 may be decisive to determine events that modify the permeability properties of cancer cell membranes and facilitate cell proliferation (52, 53).

Despite these and other major advances, the precise function of SND1 in normal and challenged cells is not fully clarified. SND1 function and *SND1* transcription regulation are inseparable. Nevertheless, as is often the case, there is a surprisingly limited knowledge of the molecular mechanisms and agents that regulate SND1 production at the transcription level under the above-mentioned pathophysiological conditions.

After briefly summarizing the *SND1* genomic context, the present review will mainly focus on the human *SND1* promoter characterization. We provide a comprehensive description of the transcription factors and signal transduction pathways that trigger *SND1* promoter activation in different cell types and conditions.

THE HUMAN *SND1* GENE

Orthologues of *SND1* are found in mammals (5, 14, 54), plants (4), *Drosophila*, *C. elegans* (9), and many other species. The main characteristics of the gene, transcript, protein and gene promoter for *Homo sapiens* and for the two most common rodents *Mus musculus* and *Rattus norvegicus* are shown in **Table 1**. The genomic context of human *SND1* is the large arm of the chromosome 7 (7q32.1), while *Snd1* is assigned to chromosome 4 (4q23) in the rat (55) and to chromosome 6 in the mouse. It is worth mentioning that the large arm of human chromosome 7 is associated with chromosomal instability and many types of neoplasia (56).

The human and rodent genes expand 400-455 kb and contain 24 exons with identical organization, and conserved intron-exon boundary sequences in agreement with the canonical GT/AG rule. The transcription initiation site of the human gene was mapped at exon 1, while the rat *Snd1* gene pointed to the existence of two different transcription start sites, the main one being assigned to the G at position 216 upstream of the ATG codon and the secondary start point 34 bp downstream (57). *SND1* encodes 16 splicing variant transcripts, one of them translates into the full SND1 protein of 910 amino acids, other codes for a 231 amino acid protein shortened in the two extremes -uncharacterized- and the others are noncoding transcripts. The mouse and rat *Snd1* proteins contain 910/909 amino acids, respectively. Sequences are 90% identical

TABLE 1 | General information of *SND1* gene, transcript, protein and promoter in humans, mouse and rat.

| | <i>Homo sapiens</i> (human) | <i>Mus musculus</i> (house mouse) | <i>Rattus norvegicus</i> (Norway rat) |
|---|--|--------------------------------------|--|
| Gene name | SND1 | Snd1 | Snd1 |
| Gene ID | ID: 27044 | ID: 56463 | ID: 64635 |
| Aliases | TDRD11, Tudor-SN, p100 | AL033314, Tudor-SN | SND p102 |
| Chromosome | 7 | 6 | 4 |
| Location | NC_000007.14 (127651989..128092609) | NC_000072.6 (28480315..28935162) | NC_005103.4 (55772377..56171669) |
| Length (bases) | 440,621 | 454,848 | 399,293 |
| % Identity vs. human | | 87 | 84 |
| Exon counts | 24 | 24 | 24 |
| mRNA ID | NM_014390.3 | NM_019776.2 | NM_022694.2 |
| Length (bases) | 3,678 | 3,482 | 3,475 |
| % Identity vs. human | | 87 | 87 |
| Protein ID | NP_055205.2 | NP_062750.2 | NP_073185.2 |
| Aminoacids (number) | 910 | 910 | 909 |
| % Identity vs. human | | 97 | 97 |
| Promoter | EF690304 | - | AY957585 |
| Length (bases) | 3,808 | 4,600 | 1,688 |
| % Identity vs. human, Region (-300, +20) | | 82 | 84 |
| CpG island | 904 bp (-555, +349) | 850 bp (-532, +318) | 912 bp (-394, +518) |
| G-quadruplex (number), Region (-300, +20) | 4 | 2 | 3 |

Data are extracted from <https://www.ncbi.nlm.nih.gov/> database and analyzed using BLAST, UCSC Genome Browser (Dec 2013 GRCh38/hg38) and GQRS Mapper tools.

between human, rat and mouse genes and reach 97.4% for the proteins.

The genomic landscapes of the three orthologues are partially similar (Figure 2). Upstream, antisense *PAX4* and sense *FSCN3* and, downstream, sense *miR-129-1* are conserved. Complexity of intragenic elements is far greater in the human compared with the murine genes. Although *LRRC4*, a gene involved in the normal development and tumorigenesis of the nervous system, is shared by the three orthologues in antisense orientation, there are two overlapping intronic elements in the same strand orientation as the host gene that are unique to human *SND1*: *miRNA-593* and the *SND1* intronic transcript 1 (*SND1-IT1*). These elements map at introns 17 and 16, respectively.

Despite being defined as a long noncoding RNA gene, *SND1-IT1* has the capacity of encoding an uncharacterized protein called brain and nasopharyngeal carcinoma susceptibility protein NAG8. Low levels of a different noncoding intronic transcript derived from *SND1* have been detected in clear cell renal carcinoma (58). This novel transcript maps at the yet uncharacterized intron 14.

Using the genomic resources miRBase and Ensembl, Godnic et al. identified 27 miRNA/host gene pairs with cross-species conserved location (59). Among them, the pair *miRNA-593/SND1* is of particular interest for being a miRNA gene located within a gene encoding for a component of the miRNA silencing machinery. The *miR-593* gene has been linked to certain diseases, including breast cancer (60), esophageal cancer (61), and pediatric medulloblastoma (62), and is considered a non-invasive diagnostic biomarker for children with combined pituitary deficiency (63). Likewise, Fan et al. demonstrated a role for the BRCA1-mir-593-5p-MFF axis in cisplatin sensitivity in tongue squamous cell carcinoma (64).

Whether transcription initiation regions of intragenic miRNAs are into or separate from the promoter of their host genes is a matter under intense study. Approximately 50%


of the intragenic miRNAs are known to be expressed from the introns of their host genes (65), whereas about one-third of the intronic miRNAs have transcription initiation sites different from the host gene promoter (66). Intriguingly, the miRNA-593-5p is an intronic miRNA in the *SND1* gene whose BRCA1 binding site is within the *SND1* gene sequence (64). In analyzing the 5-kb region upstream of *miR-593-5p*, Fan et al. found that BRCA1 transactivated indeed miR-593-5p expression increasing its promoter activity. By contrast, they observed that BRCA1 overexpression failed to alter substantially *SND1* mRNA levels (64), suggesting that this miRNA/host gene pair does not share the transcription start sites.

THE *SND1* PROMOTER

Understanding a protein-coding gene promoter not only provides a deep insight into the regulation of gene expression but also sheds light on the protein function. We will review the current knowledge available on the *SND1* promoter architecture and the set of transcription factors that bind the proximal promoter. We also describe an *in silico* analysis of the quadruplex forming G-rich sequences that could alter *SND1* promoter shape and activity.

Basal *SND1* Expression

Our own previous studies provided the isolation and characterization of a 3,808 bp sequence of the human *SND1* gene promoter (GenBank ID: EF690304) (67), and a region of 1,688 bp corresponding to the rat *Snd1* promoter (GenBank ID: AY957585) (57). Comparing the *Homo sapiens* and *Rattus Norvegicus* genome databases we found 84% identity in a 300 bp region upstream to the transcription start point of the isolated promoter sequences of *SND1* (Table 1). Similar identity (82%) was found in the same region of the 5' flanking region of the mouse *Snd1* (Table 1). The high sequence similarities between



species point to the presence of conserved pattern of *cis*-elements that are critical for the protein expression regulation along evolution.

Bioinformatic analysis of the promoter sequences revealed multiple *cis*-acting elements and potential binding motifs for transcription factors relevant in regulating *SND1* transcription under basal and activated cellular states. We identified features characteristic of housekeeping genes, such as the absence of the canonical TATA box and the presence of CCAAT boxes and a large number of GC-sites (57, 67, 68). Most TATA-less promoters are enriched in CpG islands and CCAAT boxes near the transcription start site in specific locations for recruiting and stabilizing the transcriptional machinery. Human and rat gene promoters possess one CpG island in the region (−555, +349) and (−394, +518) respectively, with multiple GC boxes for the functional binding of Sp1 transcription factor (67, 68). Both promoters also contain two reverse CCAAT boxes, common elements in the eukaryotic genes that usually appear in the (−80, −40) region of promoters with or without TATA box (69). We demonstrated that these motifs are binding sites for NF- κ B by using immunoprecipitated chromatin from human and rat hepatoma cells (57, 67, 68). Therefore, every one of the CCAAT boxes and GC boxes are regulatory elements likely required to maintain the basal expression of *SND1* in most tissues.

Promoter activity of 5′-deletion fragments determined by luciferase reporter assays in human and rat hepatoma cells revealed a minimal promoter at −112 bp and an enhancer region between −112 and −274 bp that accounted for the maximal transcriptional activity of the proximal promoters (67, 68). As **Figure 3A** shows, this region contains two CCAAT boxes at position −28 and −61 in the human promoter and six GC boxes conserved in the rat homologue that are recognized by NF- κ B and Sp1 and assess the efficient transcription of the *SND1* gene family. Functionality of these elements was confirmed in mutation experiments (67, 68).

Regulatory Elements Associated With *SND1* Expression

Beyond the conserved *cis*-elements in *SND1* proximal promoter, we characterized a number of regulatory elements that control *SND1* promoter activity in adaptation to cell environment changes. These elements receive inputs from a multitude of stimuli and signaling pathways through a customized collection of transcription factors that might affect *SND1* expression. Emerging information from plants (4) and animal cells has demonstrated that *SND1* protein expression changes in response to cellular stresses related to inflammation, tumor growth, hypoxia, heat shock, oxidative conditions, and DNA damage (12, 70, 71).


Cellular stress results in an inflammatory response mainly triggered by inflammatory cytokines such as TNF α and mediated by the activation of NF- κ B cascade. NF- κ B is the key transcription factor that induces the expression of protective genes and finally resolves the protection or death of the cell (72, 73). We reported the activation of *SND1* transcription and

the nucleocytoplasmic redistribution of *SND1* protein during the inflammatory response prompted by TNF α in human hepatoma cells (47, 67). Upregulation of *SND1* involved direct binding of NF- κ B to five target sites in the proximal promoter, as shown in **Figure 3A** (67). This response seems to be human-specific, as, although the NF- κ B binding site motif is conserved in the rat promoter, NF- κ B did not interact with that region. Whether *SND1* displays a protective role for liver cells under inflammatory conditions is an intriguing possibility that warrants future in-depth studies.

Inflammation is linked to endoplasmic reticulum (ER) stress through a crosstalk between NF- κ B, ATF6 and XBP1 signaling pathways (74). In response to ER stress, eukaryotic cells trigger various signaling cascades termed the unfolded protein response (UPR) for controlling gene transcription and switching off translation initiation. Non-translating cellular mRNAs are sequestered into cytoplasmic stress granules waiting for a later translation or degradation (75). In this sense, it is worth mentioning that *SND1* has been defined as an important protein in RNA protection due to its ability to interact with protein components of the cytoplasmic stress granules (12, 23, 24, 70, 71, 76). We presented experimental data of *SND1* protein expression and *SND1* promoter activity upregulation by pharmacological ER stress in HepG2 cells (77). We encountered a number of potential ER stress response elements in *SND1* promoter and by plasmid-mediated ATF6 overexpression demonstrated the participation of the transcription factor ATF6 in the transcriptional activation of *SND1* gene (77). ATF6 is a membrane-bound transcription factor that plays a central role in the UPR. When agents disrupt the folding of proteins in the ER, ATF6 is cleaved by sequential proteolysis to release its cytoplasmic domain, which enters the nucleus and activates protective gene transcription. Therefore, *SND1* can be added to the selective list of ATF6 target genes.

Given that the cellular processing of ATF6 activation is analogous to that undergone by sterol regulatory element binding proteins (SREBPs) in response to cholesterol deprivation, parallel activation of ATF6 and SREBP-2 in animal cells (78) may be envisioned.

In this regard, our own work revealed that *SND1* is a target gene for SREBPs. The activation of SREBP-2 in HepG2 cells cultured in the presence of the cholesterol synthesis inhibitor simvastatin or in a lipoprotein-deficient medium resulted in an increment of *SND1* promoter activity and transcript levels (79). CHIP and mutational assays confirmed the functional binding of SREBP-2 to two sites in the proximal promoter sequence containing the SRE −60 and E-box −230 motifs while SREBP-1 binding is restricted to the region with the regulatory element SRE −60 (**Figure 3B**). SREBP-gain-of function and loss-of function experiments confirmed the binding of endogenous SREBP-2 and SREBP-1 to specific sites on the *SND1* promoter. To our surprise, binding regulated *SND1* transcription in opposite ways: induction by SREBP-2 and repression by SREBP-1 overexpression (79). Such contrasting effects suggest that *SND1* expression responds to particular upstream signals recruiting selectively SREBP-1 and/or SREBP-2 in concert with a set of transcription factors to *SND1*



promoter. We now know that the optimal action of SREBPs usually requires the cooperation with other transcription factors, commonly Sp1 and NF-Y (80). The promoter of *SND1* contains conserved sites for Sp1 and NF-Y quite close to SRE -60. Preliminary findings indicate that, whereas the SREBP-2-driven activation of *SND1* promoter is independent of Sp1 and/or NF-Y, the participation of NF-Y is required for the inhibition of the *SND1* promoter activity by SREBP-1 (79). Contribution of *SND1* and SREBPs to lipid metabolism reprogramming in cancer cells may be, otherwise, expected in view of the report illustrating that deregulated cholesterol homeostasis and SREBP-2 activity is associated with *SND1* overexpression (52). We need to keep in mind that this setting facilitated hepatic cancer cell proliferation.

A recent study reported a close association between *SND1* upregulation and TGF β 1/Smad signaling pathway activation in order to promote epithelial-to-mesenchymal transition in breast cancer (25). Mechanistically, TGF β 1 triggers the activation of Smads' transcription factors and the Smad2/Smad3 complex binds specific recognizing sites located in the distal promoter of *SND1* at region (-1,100, -1,000) and (-2,100, -2,000) and enhances the transcriptional activity (25) (Figure 4). The downstream action of *SND1*, functioning as a coactivator, finally results in the disruption of cytoskeletal organization and increased cell motility and invasion and metastasis of breast cancer.

Evidence of a direct binding of c-Myb to the promoter of human *SND1* has been provided by ChIP-on-chip assays (81). c-Myb is a key transcription factor in proliferation, differentiation, and cell survival. It is activated in certain human leukaemias

and in solid cancers such as colon and breast cancer (82). In breast cancer, c-Myb interacts with transcriptional cofactors and binds to E-box and c-myb sites on the gene promoters to activate their transcription (83). By similarity, it is tempting to speculate that c-Myb may recognize certain E-box motifs within the promoter sequence of *SND1* and modulate the transcription of the gene. Nevertheless, the regulatory role of c-Myb over *SND1* promoter activity, if any, remains to be confirmed.

The ensuing conclusion is that *SND1* expression is modulated by growth factors, inflammatory cytokines, ER disruptors, and metabolic stress, all signals addressed by the transcription factors Smads, NF- κ B, ATF6, and SREBPs, and other factors still to enumerate (Figure 4). Altogether, these findings suggest the involvement of *SND1* in diverse pathways that are dysregulated in oncogenic processes. In other words, cells handle external stimuli that condition the outputs and the program of factors and cofactors that modulate the *SND1* promoter activity and the level of expression of *SND1*. Setting the level of *SND1* is crucial. A more comprehensive insight into regulation of *SND1* transcription will require understanding how the *cis*- and *trans*-regulatory elements work as a unit in the promoter.

Alternative DNA Conformations Affecting *SND1* Expression

A corollary of the above is that some aspects of gene expression are under the control of transcription factors and *cis*-acting elements in the gene promoter region in a highly dynamic manner. In addition, features beyond the primary




FIGURE 4 | Scheme illustrating the signaling pathways and transcription factors contributing to *SND1* promoter activation. *SND1* is transcriptionally upregulated by several stress settings, including TGF/Smads pathway through Smad2/3 binding, NF-κB-mediated inflammation, SREBP activation concomitant to cholesterol depletion and ATF6/XBP1-mediated endoplasmic reticulum stress.

sequence of DNA, including DNA shape and flanking sequences, can modulate binding specificity of a transcription factor to distinct sites (84). For instance, DNA sequences enriched in GC are susceptible to adopting non-B-DNA conformations such as single-stranded DNA and G-quadruplex structures. An intriguing observation is the significant enrichment of DNA G-quadruplex-forming motifs in most oncogene promoters (85).


A G-quadruplex is a four-stranded DNA structure that is composed of stacked guanine tetrads linked by loop nucleotides that can differ in their folding patterns (86). The heterogeneity of G-quadruplex structures and the potential therapeutic applications as targets for antitumor drugs have attracted intense attention during the last years (87–89). Thus, identification of G-quadruplex structures in human genes is continuously growing. G-quadruplexes in promoter regions act as important modulators of transcriptional regulation and can activate or repress gene expression (89, 90). As *SND1* is considered an oncogene, we interrogated *SND1* promoter for the possibility of G-quadruplex structures. Here we report the findings for the first time.

A set of *in silico* algorithms are available for predicting G-quadruplex structures in DNA or RNA nucleotide sequences. By using the web-based server QGRS Mapper (91) and QuadBase2 (92) we found the potential to form four G-quadruplex structures in the *SND1* proximal promoter (Figure 5A and Table 1). One exclusive sequence found at –51 in the proximal promoter of *SND1*, but not in the rat and mouse orthologues, was the best candidate to form a stable G-quadruplex structure according to the high computed scoring. The predicted structures occur in

a DNase I hypersensitivity peak located at (–287, +3) by the ENCODE group at UCSC Genome Browser (GRCh38/hg38). In general, nuclease hypersensitive sites provide information about the active transcriptional regulatory elements (93). It is particularly interesting that, in this GC-rich region, there are placed various conserved GC boxes recognized by Sp1 (Figure 3A). Whether G-quadruplexes formation masks some specific Sp1 binding sites or, instead, it confers a new binding site for an alternative factor onto *SND1* promoter and their consequences on *SND1* expression require further in-depth studies.

Figure 5B shows that there are also several putative G-quadruplex forming motifs in the 3' UTR sequence of the *SND1* transcript. G-quadruplex structures might affect miRNA binding sites and, therefore, alter *SND1* mRNA posttranscriptional processing.

Again, there is limited information relative to the posttranscriptional regulation of *SND1* gene. We know that *SND1* mRNA is modulated by microRNAs. Of particular clinical interest is the identification of miR-361-5p, miR-184 and miR-320a targeting the 3' UTR of the *SND1* transcript. It has been illustrated that overexpression of either miR-361-5p, miR-184, or miR-320a decreased cancer cell viability, migration and invasion through direct downregulation of *SND1* oncogene in gastric and colorectal cancer (94), in malignant glioma and breast cancer (34, 95) and in lung cancer cells (96). These findings rise the question about the diagnostic relevance of these miRNA/*SND1* axes and their therapeutic application as a tumor suppressive strategy for cancer treatment.



CONCLUSIONS AND FUTURE PERSPECTIVES

We are currently lacking a thorough examination about the precise role of *SND1* in normal and challenged cells. A detailed map of the *SND1* transcriptional regulation is needed. Here we illustrate the promoter architecture of *SND1* and the set of transcription factors that modulate the promoter activity and the level of transcription of *SND1*. It is relevant that *SND1* expression is under the control of transcription factors, such as NF-Y, Sp1, Smads, NF- κ B, ATF6, and SREBPs, which operate in a number of physio-pathological molecular mechanisms. Given the close connection of *SND1* with the control of cell growth and malignant transformation, *SND1* has become a novel candidate for cancer treatment and a valid molecular biomarker for prognosis and diagnosis in some cancers (32, 37, 38, 97). The inhibition of *SND1* gene and *SND1* protein is at present the focus of a number of clinical investigations.

A selective inhibitor of the *SND1* endonuclease activity, the 3'/5'-deoxythymidine bisphosphate, has succeeded in reducing hepatocellular carcinoma cells proliferation and inflammation, as well as *in vivo* tumor formation (36, 37). This inhibitor might serve as a specific nontoxic antitumor agent as it impairs the enzymatic activity-driven functions of *SND1* but is ineffective against those that are nuclease-independent. Viable options to investigate the effect of *SND1* inhibition in overcoming cancer progression are *SND1* targeting by nanoparticles-encapsulated specific siRNAs (98) as well as the generation of full or conditional *SND1* knockout mouse models. These approaches to *SND1* deletion would provide an overview about the biological significance of *SND1* and its involvement in oncogenic processes and normal development.

Aforementioned findings about the *SND1* promoter regulation may have implications in the development of therapeutic interventions capable of acting on the transcription

of *SND1* gene directly. Regulatory elements and transcription factors that transcriptionally upregulate *SND1* are commonly involved in oncogenic processes. Their inhibition by genome editing or drugs exerts solid antitumor effects (99, 100). An important question to address is how the inhibition of each transcription factor can affect the oncogenic functions of *SND1* and whether their combination with *SND1* endonuclease inhibitors may offer clinical benefits.

A particularly promising aspect to challenge as potential targets to downregulate *SND1* overexpression in tumor cells is the potential presence of functional G-quadruplex forming motifs in the promoter region of *SND1*. A variety of small ligands have been reported to induce the formation and stabilization of G-quadruplex structures in most oncogenes and might be used as anti-cancer drugs (87, 88). However, whether the G-quadruplex structures in the DNA may have a role, either inhibitory or activatory, in the control of *SND1* expression is unknown and a hypothesis that needs to be interrogated.

In conclusion, the functional diversity of *SND1* marks this gene as interesting for further analysis in relation with the multiple levels of regulation of *SND1* protein expression. Analysis of *SND1* orthologues using approaches such as gene overexpression, silencing, mutant analysis, transgenic and organ-specific knockout animals, could help to elucidate the role of *SND1* in normal cell growth, development and oncogenesis, and to assess whether the distorted *SND1* expression level is the cause or the consequence of the oncogenic environment. This does not rule out the possibility that the encoded protein *SND1* has protective roles throughout a series of effectors in cells undergoing certain stress types. The reported findings show features supporting both sides of the coin.

AUTHOR CONTRIBUTIONS

MJM, YC, and BO conceived the study and wrote the manuscript. All authors approved the final manuscript.

FUNDING

Work in the authors' lab is supported by Spanish Ministry of Economy, Industry and Competitiveness grants SAF-2015-64352-R and RTC-2015-3693-1 and Basque Government grants IT-971-16 and KK2018-00090.

REFERENCES

- Broadhurst MK, Wheeler TT. The p100 coactivator is present in the nuclei of mammary epithelial cells and its abundance is increased in response to prolactin in culture and in mammary tissue during lactation. *J Endocrinol.* (2001) 171:329–37. doi: 10.1677/joe.0.1710329
- Zhao CT, Shi KH, Su Y, Liang LY, Yan Y, Postlethwait J, et al. Two variants of zebrafish p100 are expressed during embryogenesis and regulated by nodal signaling. *FEBS Lett.* (2003) 543:190–5. doi: 10.1016/S0014-5793(03)00445-9
- Hossain MJ, Korde R, Singh PK, Kanodia S, Ranjan R, Ram G, et al. *Plasmodium falciparum* Tudor Staphylococcal Nuclease interacting proteins suggest its role in nuclear as well as splicing processes. *Gene* (2010) 468:48–57. doi: 10.1016/j.gene.2010.08.004
- dit Frey NF, Muller P, Jammes F, Kizis D, Leung J, Perrot-Rechenmann C, et al. The RNA binding protein Tudor-SN is essential for stress tolerance and stabilizes levels of stress-responsive mRNAs encoding secreted proteins in Arabidopsis. *Plant Cell* (2010) 22:1575–91. doi: 10.1105/tpc.109.070680
- Callebaut I, Mornon JP. The human EBNA-2 coactivator p100: multidomain organization and relationship to the staphylococcal nuclease fold and to the tudor protein involved in *Drosophila melanogaster* development. *Biochem J.* (1997) 321:125–32. doi: 10.1042/bj3210125
- Li CL, Yang WZ, Chen YP, Yuan HS. Structural and functional insights into human Tudor-SN, a key component linking RNA interference and editing. *Nucleic Acids Res.* (2008) 36:3579–89. doi: 10.1093/nar/gkn236
- Friberg A, Corsini L, Mourao A, Sattler M. Structure and ligand binding of the extended Tudor domain of *D. melanogaster* Tudor-SN. *J Mol Biol.* (2009) 387:921–34. doi: 10.1016/j.jmb.2009.02.018
- Lu R, Wang GG. Tudor: a versatile family of histone methylation 'readers'. *Trends Biochem Sci.* (2013) 38:546–55. doi: 10.1016/j.tibs.2013.08.002
- Caudy AA, Ketting RF, Hammond SM, Denli AM, Bathoorn AM, Tops BB, et al. A micrococcal nuclease homologue in RNAi effector complexes. *Nature* (2003) 425:411–4. doi: 10.1038/nature01956
- Li CL, Yang WZ, Shi Z, Yuan HS. Tudor staphylococcal nuclease is a structure-specific ribonuclease that degrades RNA at unstructured regions during microRNA decay. *RNA* (2018) 24:739–48. doi: 10.1261/rna.064501.117
- Jariwala N, Rajasekaran D, Srivastava J, Gredler R, Akiel MA, Robertson CL, et al. Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review). *Int J Oncol.* (2015) 46:465–73. doi: 10.3892/ijo.2014.2766
- Gutierrez-Beltran E, Denisenko TV, Zhivotovsky B, Bozhkov PV. Tudor staphylococcal nuclease: biochemistry and functions. *Cell Death Differ.* (2016) 23:1739–48. doi: 10.1038/cdd.2016.93
- Chidambaranathan-Reghupaty S, Mendoza R, Fisher PB, Sarkar D. The multifaceted oncogene SND1 in cancer: focus on hepatocellular carcinoma. *Hepatoma Res.* (2018) 4:32. doi: 10.20517/2394-5079.2018.34
- Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIIE. *Mol Cell Biol.* (1995) 15:4735–44. doi: 10.1128/MCB.15.9.4735
- Levrson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash AB, et al. Pim-1 kinase and p100 cooperate to enhance c-Myb activity. *Mol Cell* (1998) 2:417–25. doi: 10.1016/S1097-2765(00)80141-0
- Yang J, Aittomaki S, Pesu M, Carter K, Saarinen J, Kalkkinen N, et al. Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. *EMBO J.* (2002) 21:4950–8. doi: 10.1093/emboj/cdf463
- Paukku K, Yang J, Silvennoinen O. Tudor and nuclease-like domains containing protein p100 function as coactivators for signal transducer and activator of transcription 5. *Mol Endocrinol.* (2003) 17:1805–14. doi: 10.1210/me.2002-0256
- Su C, Zhang C, Teclé A, Fu X, He J, Song J, et al. Tudor staphylococcal nuclease (Tudor-SN), a novel regulator facilitating G1/S phase transition, acting as a co-activator of E2F-1 in cell cycle regulation. *J Biol Chem.* (2015) 290:7208–20. doi: 10.1074/jbc.M114.625046
- Duan Z, Zhao X, Fu X, Su C, Xin L, Saarikettu J, et al. Tudor-SN, a novel coactivator of peroxisome proliferator-activated receptor gamma protein, is essential for adipogenesis. *J Biol Chem.* (2014) 289:8364–74. doi: 10.1074/jbc.M113.523456
- Yang J, Valineva T, Hong J, Bu T, Yao Z, Jensen ON, et al. Transcriptional co-activator protein p100 interacts with snRNP proteins and facilitates the assembly of the spliceosome. *Nucleic Acids Res.* (2007) 35:4485–94. doi: 10.1093/nar/gkm470
- Gao X, Zhao X, Zhu Y, He J, Shao J, Su C, et al. Tudor staphylococcal nuclease (Tudor-SN) participates in small ribonucleoprotein (snRNP) assembly via interacting with symmetrically dimethylated Sm proteins. *J Biol Chem.* (2012) 287:18130–41. doi: 10.1074/jbc.M111.311852
- Elbarbary RA, Miyoshi K, Hedaya O, Myers JR, Maquat LE. UPF1 helicase promotes TSN-mediated miRNA decay. *Genes Dev.* (2017) 31:1483–93. doi: 10.1101/gad.303537.117
- Gao X, Ge L, Shao J, Su C, Zhao H, Saarikettu J, et al. Tudor-SN interacts with and co-localizes with G3BP in stress granules under stress conditions. *FEBS Lett.* (2010) 584:3525–32. doi: 10.1016/j.febslet.2010.07.022
- Weissbach R, Scadden AD. Tudor-SN and ADAR1 are components of cytoplasmic stress granules. *RNA.* (2012) 18:462–71. doi: 10.1261/rna.027656.111
- Yu L, Liu X, Cui K, Di Y, Xin L, Sun X, et al. SND1 acts downstream of TGFbeta1 and upstream of smurf1 to promote breast cancer metastasis. *Cancer Res.* (2015) 75:1275–86. doi: 10.1158/0008-5472.CAN-14-2387
- Rajasekaran D, Jariwala N, Mendoza RG, Robertson CL, Akiel MA, Dozmorov M, et al. Staphylococcal nuclease and tudor domain containing 1 (SND1 Protein) promotes hepatocarcinogenesis by inhibiting monoglyceride lipase (MGLL). *J Biol Chem.* (2016) 291:10736–46. doi: 10.1074/jbc.M116.715359
- Tsuchiya N, Ochiai M, Nakashima K, Ubagai T, Sugimura T, Nakagama H. SND1, a component of RNA-induced silencing complex, is up-regulated in human colon cancers and implicated in early stage colon carcinogenesis. *Cancer Res.* (2007) 67:9568–76. doi: 10.1158/0008-5472.CAN-06-2707
- Ho J, Kong JW, Choong LY, Loh MC, Toy W, Chong PK, et al. Novel breast cancer metastasis-associated proteins. *J Proteome Res.* (2009) 8:583–94. doi: 10.1021/pr8007368
- Kuruma H, Kamata Y, Takahashi H, Igarashi K, Kimura T, Miki K, et al. Staphylococcal nuclease domain-containing protein 1 as a potential tissue marker for prostate cancer. *Am J Pathol.* (2009) 174:2044–50. doi: 10.2353/ajpath.2009.080776
- Blanco MA, Aleckovic M, Hua Y, Li T, Wei Y, Xu Z, et al. Identification of staphylococcal nuclease domain-containing 1 (SND1) as a Metadherin-interacting protein with metastasis-promoting functions. *J Biol Chem.* (2011) 286:19982–92. doi: 10.1074/jbc.M111.240077
- Sand M, Skrygan M, Georgas D, Sand D, Gambichler T, Altmeyer P, et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. *Cell Tissue Res.* (2012) 350:119–26. doi: 10.1007/s00441-012-1446-0
- Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB

- and miR-221. *J Biol Chem.* (2012) 287:13952–8. doi: 10.1074/jbc.M111.321646
33. Zagryazhskaya A, Surova O, Akbar NS, Allavena G, Gyuraszova K, Zborovskaya IB, et al. Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11. *Oncotarget* (2015) 6:12156–73. doi: 10.18632/oncotarget.3495
 34. Emdad L, Janjic A, Alzubi MA, Hu B, Santhekadur PK, Menezes ME, et al. Suppression of miR-184 in malignant gliomas upregulates SND1 and promotes tumor aggressiveness. *Neuro Oncol.* (2015) 17:419–29. doi: 10.1093/neuonc/nou220
 35. Santhekadur PK, Akiel M, Emdad L, Gredler R, Srivastava J, Rajasekaran D, et al. Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFbeta signaling. *FEBS Open Bio.* (2014) 4:353–61. doi: 10.1016/j.fob.2014.03.012
 36. Jariwala N, Rajasekaran D, Mendoza RG, Shen XN, Siddiq A, Akiel MA, et al. Oncogenic role of SND1 in development and progression of hepatocellular carcinoma. *Cancer Res.* (2017) 77:3306–16. doi: 10.1158/0008-5472.CAN-17-0298
 37. Yoo BK, Santhekadur PK, Gredler R, Chen D, Emdad L, Bhutia S, et al. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. *Hepatology* (2011) 53:1538–48. doi: 10.1002/hep.24216
 38. Yin J, Ding J, Huang L, Tian X, Shi X, Zhi L, et al. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression. *Anat Rec.* (2013) 296:1568–75. doi: 10.1002/ar.22737
 39. Cappellari M, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Saarikettu J, et al. The transcriptional co-activator SND1 is a novel regulator of alternative splicing in prostate cancer cells. *Oncogene* (2014) 33:3794–802. doi: 10.1038/onc.2013.360
 40. Elbarbary RA, Miyoshi K, Myers JR, Du P, Ashton JM, Tian B, et al. Tudor-SN-mediated endonucleolytic decay of human cell microRNAs promotes G1/S phase transition. *Science* (2017) 356:859–62. doi: 10.1126/science.aai9372
 41. Cui X, Zhao C, Yao X, Qian B, Su C, Ren Y, et al. SND1 acts as an anti-apoptotic factor via regulating the expression of lncRNA UCA1 in hepatocellular carcinoma. *RNA Biol.* (2018) 15:1364–75. doi: 10.1080/15476286.2018.1534525
 42. Fashe T, Saarikettu J, Isomaki P, Yang J, Silvennoinen O. Expression analysis of Tudor-SN protein in mouse tissues. *Tissue Cell* (2013) 45:21–31. doi: 10.1016/j.tice.2012.09.001
 43. Keenan TW, Winter S, Rackwitz HR, Heid HW. Nuclear coactivator protein p100 is present in endoplasmic reticulum and lipid droplets of milk secreting cells. *Biochim Biophys Acta* (2000) 1523:84–90. doi: 10.1016/S0304-4165(00)00106-9
 44. Fresnedo O, De Heredia ML, Martinez MJ, Cristobal S, Rejas MT, Cuezva JM, et al. Immunolocalization of a novel cholesteryl ester hydrolase in the endoplasmic reticulum of murine and human hepatocytes. *Hepatology* (2001) 33:662–7. doi: 10.1053/jhep.2001.22763
 45. Garcia-Arcos I, Rueda Y, Gonzalez-Kother P, Palacios L, Ochoa B, Fresnedo O. Association of SND1 protein to low density lipid droplets in liver steatosis. *J Physiol Biochem.* (2010) 66:73–83. doi: 10.1007/s11745-010-3492-2
 46. Valineva T, Yang J, Palovuori R, Silvennoinen O. The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. *J Biol Chem.* (2005) 280:14989–96. doi: 10.1074/jbc.M410465200
 47. Arretxe E, Armengol S, Mula S, Chico Y, Ochoa B, Martinez MJ. Profiling of promoter occupancy by the SND1 transcriptional coactivator identifies downstream glycerolipid metabolic genes involved in TNFalpha response in human hepatoma cells. *Nucleic Acids Res.* (2015) 43:10673–88. doi: 10.1093/nar/gkv858
 48. Santos CR, Schulze A. Lipid metabolism in cancer. *FEBS J.* (2012) 279:2610–23. doi: 10.1111/j.1742-4658.2012.08644.x
 49. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr. Cellular fatty acid metabolism and cancer. *Cell Metab.* (2013) 18:153–61. doi: 10.1016/j.cmet.2013.05.017
 50. Ao J, Wei C, Si Y, Luo C, Lv W, Lin Y, et al. Tudor-SN regulates milk synthesis and proliferation of bovine mammary epithelial cells. *Int J Mol Sci.* (2015) 16:29936–47. doi: 10.3390/ijms161226212
 51. Palacios L, Ochoa B, Gomez-Lechon MJ, Castell JV, Fresnedo O. Overexpression of SND p102, a rat homologue of p100 coactivator, promotes the secretion of lipoprotein phospholipids in primary hepatocytes. *Biochim Biophys Acta* (2006) 1761:698–708. doi: 10.1016/j.bbaliip.2006.05.005
 52. Navarro-Imaz H, Rueda Y, Fresnedo O. SND1 overexpression deregulates cholesterol homeostasis in hepatocellular carcinoma. *Biochim Biophys Acta* (2016) 1861:988–96. doi: 10.1016/j.bbaliip.2016.05.011
 53. Navarro-Imaz H, Chico Y, Rueda Y, Fresnedo O. Channeling of newly synthesized fatty acids to cholesterol esterification limits triglyceride synthesis in SND1-overexpressing hepatoma cells. *Biochim Biophys Acta Mol Cell Biol Lipids* (2019) 1864:137–46. doi: 10.1016/j.bbaliip.2018.11.004
 54. Ponting CP. P100, a transcriptional coactivator, is a human homologue of staphylococcal nuclease. *Protein Sci.* (1997) 6:459–63. doi: 10.1002/pro.5560060224
 55. Lienard P, Riviere M, Van VP, Szpirer C, Szpirer J. Assignment of SND1, the gene encoding coactivator p100, to human chromosome 7q31.3 and rat chromosome 4q23 by *in situ* hybridization. *Cytogenet Cell Genet.* (2000) 90:253–4. doi: 10.1159/000056783
 56. Ma K, Qiu L, Mrasek K, Zhang J, Liehr T, Quintana LG, et al. Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. *Int J Mol Sci.* (2012) 13:11974–99. doi: 10.3390/ijms130911974
 57. Rodriguez L, Bartolome N, Ochoa B, Martinez MJ. Isolation and characterization of the rat SND p102 gene promoter: putative role for nuclear factor-Y in regulation of transcription. *Ann N Y Acad Sci.* (2006) 1091:282–95. doi: 10.1196/annals.1378.074
 58. Brito GC, Fachel AA, Vettore AL, Vignal GM, Gimba ER, Campos FS, et al. Identification of protein-coding and intronic noncoding RNAs down-regulated in clear cell renal carcinoma. *Mol Carcinog.* (2008) 47:757–67. doi: 10.1002/mc.20433
 59. Godnic I, Zorc M, Jevsinek SD, Calin GA, Horvat S, Dovc P, et al. Genome-wide and species-wide *in silico* screening for intragenic MicroRNAs in human, mouse and chicken. *PLoS ONE* (2013) 8:e65165. doi: 10.1371/journal.pone.0065165
 60. Nygren MK, Tekle C, Ingebrigtsen VA, Makela R, Krohn M, Aure MR, et al. Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. *Br J Cancer* (2014) 110:2072–80. doi: 10.1038/bjc.2014.113
 61. Ito T, Sato F, Kan T, Cheng Y, David S, Agarwal R, et al. Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer. *Int J Cancer* (2011) 129:2134–46. doi: 10.1002/ijc.25874
 62. Pezuk JA, Brassesco MS, de Oliveira RS, Machado HR, Neder L, Scrideli CA, et al. PLK1-associated microRNAs are correlated with pediatric medulloblastoma prognosis. *Childs Nerv Syst.* (2017) 33:609–15. doi: 10.1007/s00381-017-3366-5
 63. Hu Y, Wang Q, Wang Z, Wang F, Guo X, Li G. Circulating microRNA profiles and the identification of miR-593 and miR-511 which directly target the PROP1 gene in children with combined pituitary hormone deficiency. *Int J Mol Med.* (2015) 35:358–66. doi: 10.3892/ijmm.2014.2016
 64. Fan S, Liu B, Sun L, Lv XB, Lin Z, Chen W, et al. Mitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis. *Oncotarget* (2015) 6:14885–904. doi: 10.18632/oncotarget.3659
 65. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. *Genome Res.* (2004) 14:1902–10. doi: 10.1101/gr.2722704
 66. Oszolac F, Poling LL, Wang Z, Liu H, Liu XS, Roeder RG, et al. Chromatin structure analyses identify miRNA promoters. *Genes Dev.* (2008) 22:3172–83. doi: 10.1101/gad.1706508
 67. Armengol S, Arretxe E, Rodriguez L, Ochoa B, Chico Y, Martinez MJ. NF-kappaB, Sp1 and NF-Y as transcriptional regulators of human SND1 gene. *Biochimie* (2013) 95:735–42. doi: 10.1016/j.biochi.2012.10.029
 68. Rodriguez L, Ochoa B, Martinez MJ. NF-Y and Sp1 are involved in transcriptional regulation of rat SND p102 gene. *Biochem Biophys Res Commun.* (2007) 356:226–32. doi: 10.1016/j.bbrc.2007.02.110

69. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. *Nucleic Acids Res.* (1998) 26:1135–43. doi: 10.1093/nar/26.5.1135
70. Su C, Gao X, Yang W, Zhao Y, Fu X, Cui X, et al. Phosphorylation of Tudor-SN, a novel substrate of JNK, is involved in the efficient recruitment of Tudor-SN into stress granules. *Biochim Biophys Acta* (2017) 1864:562–71. doi: 10.1016/j.bbamcr.2016.12.018
71. Fu X, Zhang C, Meng H, Zhang K, Shi L, Cao C, et al. Oncoprotein Tudor-SN is a key determinant providing survival advantage under DNA damaging stress. *Cell Death Differ.* (2018) 25:1625–37. doi: 10.1038/s41418-018-0068-9
72. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. *Nature* (2004) 431:461–6. doi: 10.1038/nature02924
73. Wullaert A, van LG, Heynink K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. *Endocr Rev.* (2007) 28:365–86. doi: 10.1210/er.2006-0031
74. Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. *J Hepatol.* (2011) 54:795–809. doi: 10.1016/j.jhep.2010.11.005
75. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. *Science* (2011) 334:1081–6. doi: 10.1126/science.1209038
76. Gao X, Shi X, Fu X, Ge L, Zhang Y, Su C, et al. Human Tudor staphylococcal nuclease (Tudor-SN) protein modulates the kinetics of AGTR1-3'UTR granule formation. *FEBS Lett.* (2014) 588:2154–61. doi: 10.1016/j.febslet.2014.04.045
77. Armengol S, Arretxe E, Enzunza L, Mula S, Ochoa B, Chico Y, et al. The promoter of cell growth- and RNA protection-associated SND1 gene is activated by endoplasmic reticulum stress in human hepatoma cells. *BMC Biochem.* (2014) 15:25. doi: 10.1186/s12858-014-0025-2
78. Ye J, Rawson RB, Komuro R, Chen X, Dave UP, Prywes R, et al. ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. *Mol Cell* (2000) 6:1355–64. doi: 10.1016/S1097-2765(00)00133-7
79. Armengol S, Arretxe E, Enzunza L, Llorente I, Mendibil U, Navarro-Imaz H, et al. SREBP-2-driven transcriptional activation of human SND1 oncogene. *Oncotarget* (2017) 8:108181–94. doi: 10.18632/oncotarget.22569
80. Reed BD, Charos AE, Szekely AM, Weissman SM, Snyder M. Genome-wide occupancy of SREBP1 and its partners NFY and SP1 reveals novel functional roles and combinatorial regulation of distinct classes of genes. *PLoS Genet.* (2008) 4:e1000133. doi: 10.1371/journal.pgen.1000133
81. Quintana AM, Liu F, O'Rourke JP, Ness SA. Identification and regulation of c-Myb target genes in MCF-7 cells. *BMC Cancer* (2011) 11:30. doi: 10.1186/1471-2407-11-30
82. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. *Nat Rev Cancer* (2008) 8:523–34. doi: 10.1038/nrc2439
83. Jin W, Liu Y, Chen L, Zhu H, Di GH, Ling H, et al. Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. *Breast Cancer Res Treat.* (2011) 125:699–713. doi: 10.1007/s10549-010-0876-1
84. Kouzine F, Levens D, Baranello L. DNA topology and transcription. *Nucleus* (2014) 5:195–202. doi: 10.4161/nucl.28909
85. Brooks TA, Kendrick S, Hurley L. Making sense of G-quadruplex and i-motif functions in oncogene promoters. *FEBS J.* (2010) 277:3459–69. doi: 10.1111/j.1742-4658.2010.07759.x
86. Qin Y, Hurley LH. Structures, folding patterns, and functions of intramolecular DNA G-quadruplexes found in eukaryotic promoter regions. *Biochimie* (2008) 90:1149–71. doi: 10.1016/j.biochi.2008.02.020
87. Ou TM, Lu YJ, Tan JH, Huang ZS, Wong KY, Gu LQ. G-quadruplexes: targets in anticancer drug design. *ChemMedChem.* (2008) 3:690–713. doi: 10.1002/cmdc.200700300
88. Balasubramanian S, Hurley LH, Neidle S. Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? *Nat Rev Drug Discov.* (2011) 10:261–75. doi: 10.1038/nrd3428
89. Kwok CK, Merrick CJ. G-Quadruplexes: prediction, characterization, and biological application. *Trends Biotechnol.* (2017) 35:997–1013. doi: 10.1016/j.tibtech.2017.06.012
90. Maizels N. G4-associated human diseases. *EMBO Rep.* (2015) 16:910–22. doi: 10.15252/embr.201540607
91. Kikin O, D'Antonio L, Bagga PS. QGRS Mapper: a web-based server for predicting G-quadruplexes in nucleotide sequences. *Nucleic Acids Res.* (2006) 34:W676–82. doi: 10.1093/nar/gkl253
92. Dhapola P, Chowdhury S. QuadBase2: web server for multiplexed guanine quadruplex mining and visualization. *Nucleic Acids Res.* (2016) 44:W277–83. doi: 10.1093/nar/gkw425
93. Boyle AP, Davis S, Shulha HP, Meltzer P, Margulies EH, Weng Z, et al. High-resolution mapping and characterization of open chromatin across the genome. *Cell* (2008) 132:311–22. doi: 10.1016/j.cell.2007.12.014
94. Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin C, et al. MiR-361-5p inhibits colorectal and gastric cancer growth and metastasis by targeting staphylococcal nuclease domain containing-1. *Oncotarget* (2015) 6:17404–16. doi: 10.18632/oncotarget.3744
95. Li QQ, Zhang L, Wan HY, Liu M, Li X, Tang H. CREB1-driven expression of miR-320a promotes mitophagy by down-regulating VDAC1 expression during serum starvation in cervical cancer cells. *Oncotarget* (2015) 6:34924–40. doi: 10.18632/oncotarget.5318
96. Xing A, Pan L, Gao J. p100 functions as a metastasis activator and is targeted by tumor suppressing microRNA-320a in lung cancer. *Thorac Cancer* (2018) 9:152–8. doi: 10.1111/1759-7714.12564
97. Gu X, Xue J, Ai L, Sun L, Zhu X, Wang Y, et al. SND1 expression in breast cancer tumors is associated with poor prognosis. *Ann N Y Acad Sci.* (2018) 1433:53–60. doi: 10.1111/nyas.13970
98. Rajasekaran D, Srivastava J, Ebeid K, Gredler R, Akiel M, Jariwala N, et al. Combination of nanoparticle-delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and all-trans retinoic acid (ATRA): an effective therapeutic strategy for Hepatocellular Carcinoma (HCC). *Bioconjug Chem.* (2015) 26:1651–61. doi: 10.1021/acs.bioconjchem.5b00254
99. Moslehi A, Hamidi-Zad Z. Role of SREBPs in liver diseases: a mini-review. *J Clin Transl Hepatol.* (2018) 6:332–8. doi: 10.14218/JCTH.2017.00061
100. Kaltschmidt B, Greiner JFW, Kadhim HM, Kaltschmidt C. Subunit-specific role of NF-kB in cancer. *Biomedicines* (2018) 6:E44. doi: 10.3390/biomedicines6020044

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Ochoa, Chico and Martínez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.